News and Announcements
Manufacturing Serendipity: The Art of Taking Your Business from Unknown to Known
- Published June 08, 2023 4:00AM UTC
- Publisher Wholesale Investor
- Categories Capital Raising Tips
As a founder, your ultimate goal is to make your business known, whether it is for attracting clients, staff, or investors. But how can people buy from you, work for you, or invest in you if they don’t know about you? This is where manufacturing serendipity comes in.
In the world of capital raising, your job is to create opportunities for chance encounters that could potentially change the trajectory of your business.
However, it is important to understand the psychology behind this process. You need to meet a lot of people to find the right one, and it only takes one person to make a significant impact on your business.
In this video, we dive deep into the art of manufacturing serendipity and discuss the different ways you can build awareness in your capital raise. We also provide actionable tips to help you improve your chances of meeting the right people and making meaningful connections. Don’t miss out on the power of serendipity in your capital raise!
Capital Raising Tips
Funding the Future: The Strategic Power of Venture Debt in a Volatile Market
Discover Martin Tang’s perspective on the evolving venture debt landscape in Southeast Asia, its strategic advantages over traditional VC, and its importance in navigating the current economic climate.
From Desert to Dairy: How Australia’s Wild Camels and Good Earth Dairy’s Technology are Transforming Infant Formula
“In the heart of Australia’s outback, an innovative dairy company is harnessing the world’s largest wild camel population to revolutionise infant nutrition, targeting the rapidly growing AUD $127B global infant formula market with hypoallergenic solutions.
World-First FDA Approval for EBR Systems’ Leadless Cardiac Device Opens US$3.6bn Market
Discover how EBR Systems’ groundbreaking WISE CRT System, the first leadless left ventricular pacing technology, has gained FDA approval, addressing limitations of traditional cardiac resynchronisation therapy.
Backed By Leading Investment Groups and Family Offices
